Completed × Squamous Cell Carcinoma of Head and Neck × Genitourinary × Clear all Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Phase 3 Completed
161 enrolled
Study of DF9001 in Patients With Advanced Solid Tumors
Phase 1/2 Completed
24 enrolled
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
Phase 1 Completed
89 enrolled
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
KEYVIBE-005
Phase 2 Completed
613 enrolled
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Phase 1 Completed
60 enrolled
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Phase 1 Completed
54 enrolled
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Phase 1/2 Completed
89 enrolled 21 charts
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Phase 1 Completed
41 enrolled
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Phase 1 Completed
67 enrolled
A Study of E7130 in Participants With Solid Tumors
Phase 1 Completed
62 enrolled
PEVOsq
Phase 2 Completed
112 enrolled
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
Phase 1/2 Completed
323 enrolled
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
Phase 1/2 Completed
26 enrolled 47 charts
DUET-3
Phase 1 Completed
198 enrolled
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
Phase 1 Completed
21 enrolled
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
Phase 1 Completed
35 enrolled
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
109 enrolled 25 charts
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Phase 1 Completed
117 enrolled
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Phase 1 Completed
14 enrolled 13 charts
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
Phase 1 Completed
11 enrolled
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Phase 1 Completed
19 enrolled
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
Phase 2 Completed
30 enrolled 20 charts
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Phase 1 Completed
38 enrolled
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
Phase NA Completed
434 enrolled
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
Phase 1 Completed
12 enrolled
DUET-4
Phase 1 Completed
78 enrolled
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Phase 1 Completed
13 enrolled 10 charts
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Phase 1/2 Completed
58 enrolled 24 charts
DUET-2
Phase 1 Completed
150 enrolled
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
52 enrolled 25 charts
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Phase 1 Completed
174 enrolled 68 charts
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
Phase 1/2 Completed
24 enrolled
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Phase 1/2 Completed
195 enrolled 51 charts
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Phase 1 Completed
40 enrolled
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
Phase 2 Completed
5 enrolled 8 charts
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
Phase 1 Completed
118 enrolled
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
Phase 1 Completed
6 enrolled 27 charts
ONCODAGE
Phase NA Completed
1,674 enrolled 9 charts
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Phase 1 Completed
22 enrolled
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
Phase 1 Completed
8 enrolled
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Phase 1/2 Completed
175 enrolled
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
Phase 1 Completed
20 enrolled
Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871
Completed
69 enrolled
High-dose ICE With Amifostine
Phase 2 Completed
24 enrolled
Docetaxel in Treating Patients With Solid Tumors
Phase 2 Completed
109 enrolled
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
Completed
98 enrolled
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
Phase 1 Completed
23 enrolled
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
Phase 1 Completed
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
Phase 1/2 Completed
66 enrolled